Intelligence · Clinical Pipeline

Sanofi-Aventis U.S Pipeline

All ClinicalTrials.gov programs at Sanofi-Aventis U.S — phase, modality, and trial IDs.

Programs: 117

Quick answer

Sanofi-Aventis U.S has 117 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Zirabev 25 mg/ml concentrate for solution for infusion, SAR445877, Erbitux 5 mg/mL solution for infusion, Zirabev 25 mg/ml concentrate for solution for infusion

Sanofi-aventis Healthcare Pty Ltd

Solid tumor

phase 2 small molecule active

1 trial
riliprubart

Sanofi-aventis Healthcare Pty Ltd

Chronic inflammatory demyelinating polyradiculoneuropathy

phase 2 small molecule active

1 trial
riliprubart, riliprubart

Sanofi-aventis Healthcare Pty Ltd

Transplant Rejection

phase 2 small molecule active

1 trial
sarilumab

Sanofi-aventis Healthcare Pty Ltd

Systemic Juvenile Idiopathic Arthritis (sJIA)

phase 2 small molecule active

1 trial
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 1 other active

1 trial
A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

Sanofi-aventis Healthcare Pty Ltd

Osteoarthritis

phase 1 other active

1 trial
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

Sanofi-aventis Healthcare Pty Ltd

Immune Thrombocytopenia Purpura

phase 1 other active

1 trial
A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases

phase 1 other active

1 trial
A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years

Sanofi-aventis Healthcare Pty Ltd

Immuun system diseases

phase 1 other active

1 trial
A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in healthy adult participants

Sanofi-aventis Healthcare Pty Ltd

Healthy Volunteer

phase 1 other active

1 trial
A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants

Sanofi-aventis Healthcare Pty Ltd

Healthy Volunteers

phase 1 other active

1 trial
A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Sanofi-aventis Healthcare Pty Ltd

Plasma cell myeloma refractory

phase 1 other active

1 trial
A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumab

Sanofi-aventis Healthcare Pty Ltd

Hemophilia A

phase 1 other active

1 trial
An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates

Sanofi-aventis Healthcare Pty Ltd

Dermatitis atopic

phase 1 other active

1 trial
Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants

Sanofi-aventis Healthcare Pty Ltd

Immune system diseases

phase 1 other active

1 trial
Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

Sanofi-aventis Healthcare Pty Ltd

Colitis ulcerative

phase 1 other active

1 trial
SAR447971 first-in-human study

Sanofi-aventis Healthcare Pty Ltd

Hidradenitis

phase 1 other active

1 trial
Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants

Sanofi-aventis Healthcare Pty Ltd

Asthma

phase 1 other active

1 trial
Dupilumab, dupilumab placebo, solution for injection in pre-filled syringe

Sanofi-aventis Healthcare Pty Ltd

Asthma

approved small molecule active

1 trial
Dupilumab, matched placebo for test product, Ventolin Evohaler 100 micrograms

Sanofi-aventis Healthcare Pty Ltd

Respiratory tract diseases

approved small molecule active

1 trial
INSULIN GLARGINE

Sanofi-aventis Healthcare Pty Ltd

Diabetes mellitus II

approved small molecule active

1 trial

Frequently asked questions

How many pipeline programs does Sanofi-Aventis U.S have?

117 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Quick answer

Zirabev 25 mg/ml concentrate for solution for infusion, SAR445877, Erbitux 5 mg/mL solution for infusion, Zirabev 25 mg/ml concentrate for solution for infusion

riliprubart

riliprubart, riliprubart

sarilumab

A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.

A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

A study to investigate how different tablet types of balinatunfib and food will influence the absorption of balinatunfib in blood in healthy adult participants

A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years

A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in healthy adult participants

A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants

A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment with emicizumab

An open-label, DDI study to investigate the effects of amlitelimab on the PK of selected cytochrome P450 substrates

Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants

Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

SAR447971 first-in-human study

Safety and tolerability of single and multiple ascending doses of lunsekimig (SAR443765) in healthy participants

Dupilumab, dupilumab placebo, solution for injection in pre-filled syringe

Dupilumab, matched placebo for test product, Ventolin Evohaler 100 micrograms

INSULIN GLARGINE

Frequently asked questions

Stay Ahead in Pharma